17 results about "Viral genomes" patented technology

Nucleotide compositions, recombinant vectors, and recombinant viral genomes are disclosed that include a modified horseradish peroxidase (HRP) gene sequence, as well as recombinant viruses that have the modified HRP gene sequence incorporated into the viral genome thereof. The recombinant viruses are utilized in an HRP-based assay to analyze the neutralization potential of candidate antiviral agents, such as antiviral antibodies.

This invention discloses a chikungunya virus genome fragment armored RNA reference, its preparation method, and its application. The preparation process involves the following steps: (1) constructing the prokaryotic expression backbone vector pACYCAR; (2) cloning the CKV genome fragment CKA (nt17-2276); (3) constructing the prokaryotic expression vector pACYCAR-CKA; (4) inducing the expression of armored RNA; and (5) purifying the armored RNA. This invention solves the technical problems of high biosafety risk, poor stability, and insufficient gene fragment coverage in existing CKV nucleic acid detection references. It fills the gap in the lack of high-quality references for CKV detection.

This invention belongs to the fields of microbial technology and veterinary pharmacology, and discloses a strain of *Alternaria alternata* isolated from Artemisia argyi, its fermentation supernatant, and its application in the preparation of anti-PRRSV drugs. The strain's preservation number is CCTCC NO: M2026443. The fermentation supernatant of this strain can inhibit PRRSV infection of cells and inhibit viral proliferation on cells. Cell-level anti-infection studies show that this strain has significant anti-PRRSV activity in vitro, reducing viral titer, viral genome copy number, and viral nucleoprotein production. It can be used to prepare a broad-spectrum anti-porcine reproductive and respiratory syndrome virus drug to control the occurrence of porcine reproductive and respiratory syndrome.

The application discloses a method for detecting viruses and virus replication in media based on Small-RNA high-throughput sequencing. The application belongs to the technical field of virus detection, and the method for identifying virus types in a to-be-detected sample by Small-RNA sequencing developed by the application comprises the following steps: 1) extracting total RNA from a virus-infected to-be-detected sample, constructing a cDNA library, and separating small RNA sequence fragments from the cDNA library; 2) downloading virus sequences and classification databases from GenBank, and comparing the small RNA sequence fragments with virus sequence files; 3) comparing a contigs3 file with a virus nucleic acid database, selecting sequences with the minimum e value in the comparison results in the contigs3 file, calculating the coverage of the contigs3 sequences in corresponding virus genomes, distinguishing virus information with a coverage threshold, and deducing the virus source of the small RNA sequence.

Methods of characterizing a preparation of biomolecules are provided. In some examples, methods of characterizing a preparation of viral particles are provided, including subjecting the preparation of viral particles to analytical ultracentrifugation under sedimentation velocity conditions, measuring sedimentation of the viral particles at a plurality of time points, determining a frictional ratio function c(s,ff0) and a sedimentation coefficient for the preparation of viral particles, plotting the c(s,ff0) versus the sedimentation coefficient(S) to obtain a c(s,ff0) distribution, and characterizing the presence and / or relative composition of viral particles comprising full viral genomes, partial viral genomes, overpackaged viral genomes, and / or empty viral particles in the preparation of viral particles.

Provided are modified cells and cell lines containing extracellular enveloped viruses (EEV), methods of producing serum-resistant EEVs, and programmed EEVs for systemic oncolytic viral therapy. The viruses are high EEV producing viruses that contain genome modifications that alter properties and / or activities of the viruses. The cells and cell lines are modified to encode polypeptides or peptides that are displayed on their membranes, which, when virus is propagated in the cells, encases the virus so that the polypeptides and peptides from the cell membrane are displayed on the virus. The viruses, thus contain modified outer envelopes that display polypeptides and / or peptides encoded by the virus and from the cell membranes. This combination provides viruses whose properties and activities can be programmed by virtue of the cells in which they are produced and viral genome modifications. The viruses can be used for treating cancers or, because the properties of the virus, including tropisms, other diseases, disorders, and conditions involving targeted cells.

Provided in the present invention is a digital standard for verifying the accuracy of the metagenome biological information detection process. In the present invention, 24 viral genomes of particular concern to the Chinese Pharmacopoeia are selected, and a total of 100 samples are constructed. Each sample contains 24 different viral genome sequences. The abundance is randomly generated, and the viral abundance distribution of each sample is different. The digital standard of the present invention can be used for verifying the accuracy of the biological information process built on the basis of metagenome.

Modified antisense mucleic acid molecules ending with or without chain terminating bases targeting the HIV-1 viral genomic RNA 3′ LTR region, and uses thereof for inhibiting HIV-1 replication and infection, are disclosed. The antisense mucleic acid molecules more specifically target a sequence corresponding to about nucleotide 9628 to about nucleotide 9642 of HIV-1 clone pNL4-3.

The application discloses a construction method of a human adenovirus type 4 protein V knockout mutant strain and application thereof, and belongs to the technical field of biotechnology. The application precisely knocks out a protein V coding sequence in a human adenovirus type 4 full-genome infectious clone by means of a Red / ET homologous recombination system combined with a ccdB reverse screening technology, and obtains a recombination plasmid pBR322-Ad4-△V-EGFP which is clear in genetic background and highly homozygous in sequence. After the plasmid is transfected into HEK-293 cells, the human adenovirus type 4 protein V knockout mutant strain obtained exhibits a typical “replication-deficient” phenotype: although a particle containing a viral genome can be packaged, the physical titer (4.76×10 6 copies / μL) of the particle is about one order of magnitude lower than that of a wild type, and the progeny virus completely loses secondary infection ability. Transcriptome analysis reveals that the deletion mutation can specifically down-regulate a host proteasome pathway and activate a natural immune response. The mutant strain is high in safety and strong in immunogenicity, and can be used as an ideal attenuated vaccine carrier or a gene therapy tool.

Disclosed herein are compositions and methods for treating arthritis (e.g., osteoarthritis or rheumatoid arthritis) in a subject. The methods provided herein include intra-articular administration to a subject in need thereof using a composition comprising one or more nucleic acids that collectively encode an interleukin-1 receptor antagonist (IL-1Ra) polypeptide and an FGF18 polypeptide. Adeno-associated virus (AAV) viral genomes and particles carrying such nucleic acids and uses thereof are further described.

This application relates to the field of biomedical technology, specifically disclosing an immune-boosting preparation that promotes HPV viral genome methylation. The preparation comprises epigallocatechin gallate, folic acid, vitamin C, vitamin E, zinc gluconate, various B vitamins, and excipients. Its preparation method involves pretreatment of the raw materials and excipients, microencapsulation of some vitamins, staged mixing via gradient shearing, dry granulation, low-temperature vacuum staged drying, and granulation to produce an oral solid dosage form. This preparation can be used to intervene in HPV infection, achieving dual intervention by promoting HPV viral genome methylation and enhancing the body's immunity. It has the advantages of a rational formulation and stable active ingredients; its preparation process effectively avoids oxidative inactivation of active ingredients, ensuring the uniformity of the preparation, and is simple to operate, suitable for large-scale production, and can meet the needs of clinical and routine HPV infection intervention.

The present invention relates to methods for producing preparations comprising recombinant adeno-associated virus (rAAV) particles. More particularly, the present invention relates to methods for producing a preparation comprising recombinant adeno-associated virus (rAAV) particles wherein an Open Reading Frame (ORF) is introduced to a host cell under suitable conditions, so that said ORF is overexpressed, and wherein said preparation comprises rAAV particles have improved and / or increased viral genome titer, capsid titer, and / or functional titer. The disclosure also provides preparations comprising recombinant adeno-associated virus (rAAV) particles having improved and / or increased viral genome titer, capsid titer, and / or functional titer.

The application discloses a Zika virus genomic fragment armoured RNA reference substance and a preparation method and application thereof, and is characterized in that the following steps are included: (1) constructing a prokaryotic expression skeleton vector pACYCAR (2) cloning a ZKV genomic fragment ZKA (nt81-2350) (3) constructing a prokaryotic expression vector pACYCAR-ZKA (4) inducing expression of armoured RNA (5) purifying the armoured RNA. The application solves the technical problems of high biological safety risk, poor stability and insufficient gene fragment coverage of existing ZKV nucleic acid detection reference substances. The application fills the blank of the lack of high-quality reference substances for ZKV detection.

The application discloses an infectious bursal disease virus attenuated vaccine strain and a construction method and application thereof, and belongs to the technical field of biotechnology. The application constructs a gene mutant strain through a gene mutation and an infectious cloning operation method, performs a synonymous mutation (TTCAGA) on a TTTCGT motif of a vp2 gene in an IBDV virus genome, and rescues the mutant strain. Compared with a parent strain, the ability of the mutant strain to induce cell apoptosis in an early infection stage is significantly reduced, and the proliferation of the virus is effectively promoted. After the mutant strain is inoculated into SPF chickens, the pathological changes of bursa of Fabricius of the SPF chickens in an early infection stage are obviously weaker than those of the chickens infected by the parent strain, and the replication ability of the mutant strain in an animal body is significantly higher than that of the parent strain. The IBDV genome mutation site provided by the application has important significance for the development of a candidate vaccine strain.

This invention discloses a crRNA target and a CRISPR-Cas13a system for detecting West Nile virus. The West Nile virus target sequence is shown in SEQ ID NO.1. The CRISPR-Cas13a system includes Cas13a protein and crRNA, or a complex of the two. The crRNA includes an anchoring sequence for binding to the Cas13a protein and a guide sequence for targeting the West Nile virus target sequence. The West Nile virus target sequence is shown in SEQ ID NO.1 and is located at positions 274-301 of the West Nile virus genome. Experiments demonstrate that the crRNA of this invention can achieve highly sensitive and specific detection of West Nile virus nucleic acid by activating Cas13a, with a sensitivity reaching one copy (1 copy / μL).

This invention provides a capture probe set for whole-genome sequencing of hepatitis A virus (HAV). The nucleotide sequences of the capture probe set are shown in SEQ ID No:1 to SEQ ID No:880. This capture probe set can be used to prepare kits for whole-genome sequencing of HAV. This invention also provides a method for whole-genome sequencing of HAV using the capture probe set. The method involves liquid-phase hybridization of a total RNA library from a sample to be tested with the capture probe set. DNA fragments hybridized with the capture probe set are isolated from the hybridization reaction solution. These DNA fragments are then used as templates for capture-and-PCR amplification. The PCR products are sequenced, and after data analysis, the full-length HAV genome sequence is obtained. The capture probe set designed in this invention can capture the HAV genome. By optimizing the probe length, it can specifically enrich ultra-low copy numbers of the viral genome from high-background host nucleic acids, showing broad application prospects.

The application provides a detection method and kit for chicken infectious anemia virus based on the nature of four-strand DNA oxidoreductase. The method uses isothermal amplification technology to amplify the genomic fragment containing the four-strand DNA sequence in the genome of chicken infectious anemia virus, and realizes rapid and visual detection of chicken infectious anemia virus by adding hematin and oxidoreductase substrate for color reaction.